Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Drugs of Abuse Screening Benefits from LoGiCal® Reference Materials

Published: Tuesday, October 30, 2012
Last Updated: Tuesday, October 30, 2012
Bookmark and Share
LoGiCal reference materials are very good quality and competitively priced.

Unilabs AB in Eskilstuna, Sweden, is taking advantage of LGC Standards’ LoGiCal reference materials to perform clinical analyses and screen for drugs of abuse, as chemist Elin Widing explained: “Unilabs is a privately owned clinical laboratory that analyses company healthcare and workplace samples, as well as samples from drug abuse centres. Samples are received from across Sweden and screened either qualitatively or semi-quantitatively using immunological assays, followed by quantitative LC-MSMS or GC-MS analysis for verification. Ready-to-use LoGiCal solutions are ideal for our purposes; it is so much simpler than weighing powders for inhouse preparation of reference materials.”

“We evaluated LoGiCal solutions of tetrahydrocannabinol (THC), zopiclone and alpha-hydroxyalprazolam, including deuterium-labelled alpha-hydroxyalprazolam as an internal standard for quantitative mass spectrometry analysis. Analyses were run in parallel with assays that were using our existing reference materials, and the results were comparable. LoGiCal reference materials are very good quality and competitively priced and, since the initial product evaluation, we have also ordered tramadol and its metabolites for our laboratory. In the future, as we purchase more reference materials, we intend to use LoGiCal solutions whenever they are available.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Iron Regulators Join War on Pathogens
Iron regulatory proteins (IRPs) play an important role in the body’s immune system.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!